Sacituzumab govitecan for metastatic triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is studying how patients with metastatic triple-negative breast cancer feel and function during treatment with sacituzumab govitecan (a targeted therapy) or standard chemotherapy, using patient-reported outcomes. It aims to better understand the real-world effectiveness and impact on quality of life in Chinese patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have metastatic triple-negative breast cancer, which means your breast cancer has spread and lacks receptors for estrogen, progesterone, and HER2.
- You must have received at least one prior treatment for your metastatic breast cancer.
- You must be either planning to receive, or have already received, sacituzumab govitecan (a targeted drug that delivers chemotherapy directly to cancer cells) alone, or chemotherapy chosen by your doctor.
- You cannot be currently participating in another controlled clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.